Chengdu Maxvax Biotechnology Co., Ltd. was founded in 2016 by Dr. Dexiang Chen in Chengdu, a leading innovation hub in southwestern China. Maxvax is a fully integrated biotechnology company focused on the development and commercialization of safe and effective immunotherapies to address current and emerging global health challenges. Our capabilities are built on proprietary adjuvant, recombinant protein, and mRNA technology platforms.

Maxvax operates five subsidiaries and employs more than 300 professionals. The company has been recognized as a National High-Tech Enterprise and a “Specialized, Sophisticated, and Innovative Small Giant” enterprise in Sichuan Province, and has been selected for the GEI China (Potential) Unicorn Enterprise List.

Our mission is to advance global public health through the development of innovative vaccines and immunotherapies for the prevention and treatment of infectious diseases and cancer.

Working closely with our team and global collaborators, Maxvax has established a diversified pipeline of both prophylactic and therapeutic vaccines targeting major unmet medical needs, with a strategic focus on infectious diseases, allergies, and cancer. Our programs span multiple stages of development, including two candidates currently in clinical trials.

Backed by leading global venture capital and investment firms, Maxvax is committed to becoming a trusted global partner in public health innovation.